Nothing Special   »   [go: up one dir, main page]

SMT201500061B - Topi adam6 - Google Patents

Topi adam6

Info

Publication number
SMT201500061B
SMT201500061B SM201500061T SM201500061T SMT201500061B SM T201500061 B SMT201500061 B SM T201500061B SM 201500061 T SM201500061 T SM 201500061T SM 201500061 T SM201500061 T SM 201500061T SM T201500061 B SMT201500061 B SM T201500061B
Authority
SM
San Marino
Prior art keywords
mice6
adam
adam mice6
Prior art date
Application number
SM201500061T
Other languages
English (en)
Italian (it)
Inventor
Sean Stevens
Andrew J Murphy
Lynn Macdonald
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45998616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201500061(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SMT201500061B publication Critical patent/SMT201500061B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/22—Heating, cooling or ventilating [HVAC] devices the heat being derived otherwise than from the propulsion plant
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/32—Cooling devices
    • B60H1/3204—Cooling devices using compression
    • B60H1/3228—Cooling devices using compression characterised by refrigerant circuit configurations
    • B60H1/32281—Cooling devices using compression characterised by refrigerant circuit configurations comprising a single secondary circuit, e.g. at evaporator or condenser side
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/32—Cooling devices
    • B60H1/3204—Cooling devices using compression
    • B60H1/323—Cooling devices using compression characterised by comprising auxiliary or multiple systems, e.g. plurality of evaporators, or by involving auxiliary cooling devices
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00642—Control systems or circuits; Control members or indication devices for heating, cooling or ventilating devices
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00007—Combined heating, ventilating, or cooling devices
    • B60H1/00021—Air flow details of HVAC devices
    • B60H2001/00185—Distribution of conditionned air
    • B60H2001/00192—Distribution of conditionned air to left and right part of passenger compartment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00007—Combined heating, ventilating, or cooling devices
    • B60H1/00021—Air flow details of HVAC devices
    • B60H2001/00185—Distribution of conditionned air
    • B60H2001/002—Distribution of conditionned air to front and rear part of passenger compartment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Thermal Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SM201500061T 2011-02-25 2015-03-11 Topi adam6 SMT201500061B (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161446895P 2011-02-25 2011-02-25
US201161497650P 2011-06-16 2011-06-16
US201261595200P 2012-02-06 2012-02-06
PCT/US2012/026416 WO2012141798A1 (en) 2011-02-25 2012-02-24 Adam6 mice

Publications (1)

Publication Number Publication Date
SMT201500061B true SMT201500061B (it) 2015-05-05

Family

ID=45998616

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201500061T SMT201500061B (it) 2011-02-25 2015-03-11 Topi adam6

Country Status (32)

Country Link
US (12) US8642835B2 (xx)
EP (7) EP2738259B1 (xx)
JP (7) JP2014507137A (xx)
KR (1) KR101387377B1 (xx)
CN (2) CN105861548B (xx)
AU (5) AU2012243291B2 (xx)
BR (1) BR112013021771B1 (xx)
CA (1) CA2820824A1 (xx)
CY (5) CY1116301T1 (xx)
DE (5) DE12192727T1 (xx)
DK (6) DK2738258T4 (xx)
ES (6) ES2748832T5 (xx)
FI (3) FI2738258T4 (xx)
HK (2) HK1201292A1 (xx)
HR (5) HRP20191895T4 (xx)
HU (5) HUE046746T2 (xx)
IL (4) IL226727A (xx)
IN (1) IN2013CN07629A (xx)
LT (4) LT2578688T (xx)
ME (3) ME03537B (xx)
MX (2) MX343009B (xx)
MY (1) MY172713A (xx)
NZ (2) NZ776770A (xx)
PL (5) PL2578688T5 (xx)
PT (5) PT2550363E (xx)
RS (5) RS59929B1 (xx)
RU (2) RU2722373C2 (xx)
SG (4) SG10201913155QA (xx)
SI (5) SI2550363T1 (xx)
SM (1) SMT201500061B (xx)
WO (1) WO2012141798A1 (xx)
ZA (1) ZA201305998B (xx)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
EP1523496B1 (en) 2002-07-18 2011-06-29 Merus B.V. Recombinant production of mixtures of antibodies
ES2408582T3 (es) 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP2311874B1 (en) 2004-07-22 2017-05-31 Erasmus University Medical Center Rotterdam Binding molecules
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
EP3241435B1 (en) * 2009-07-08 2021-05-26 Kymab Limited Animal models and therapeutic molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
RS59001B1 (sr) 2010-02-08 2019-08-30 Regeneron Pharma Miš sa zajedničkim lakim lancem
SG187673A1 (en) 2010-08-02 2013-03-28 Regeneron Pharma Mice that make binding proteins comprising vl domains
PT2550363E (pt) 2011-02-25 2015-03-16 Regeneron Pharma Ratinhos adam6
US10040826B2 (en) 2011-07-05 2018-08-07 Duke University Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens
PT3865581T (pt) * 2011-08-05 2024-10-04 Regeneron Pharmaceuticals Inc Murganhos da cadeia leve universal humanizada
JP5813880B2 (ja) 2011-09-19 2015-11-17 カイマブ・リミテッド ヒトへの使用に合わせて作製された抗体、可変ドメインおよび鎖
EP3741862A1 (en) 2011-09-19 2020-11-25 Kymab Limited Animals, repertoires & methods for the production of human antibodies
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
CA2850745C (en) 2011-10-03 2022-12-13 Duke University Vaccine
BR112014008775A8 (pt) * 2011-10-17 2017-09-12 Regeneron Pharma Métodos para produzir camundongos com locus restrito de cadeia pesada de imunoglobulina, para obter célula ou tecido de camundongos, para produzir sequência de ácido nucleico que codifica domínio variável de cadeia pesada humano, bem como ácido nucleico
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
SG10201605675WA (en) 2011-12-20 2016-09-29 Regeneron Pharma Humanized light chain mice
NZ734504A (en) * 2012-02-01 2022-10-28 Regeneron Pharma Humanized rodents that express heavy chains containing vl domains
AU2013204581B2 (en) 2012-03-16 2015-06-25 Regeneron Pharmaceuticals, Inc. Non-human animals expressing pH-sensitive immunoglobulin sequences
DK2825037T3 (da) 2012-03-16 2019-07-29 Regeneron Pharma Gnavere, der udtrykker pH-sensitive immunoglobulinsekvenser
WO2013138680A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
NZ799532A (en) 2012-04-20 2023-07-28 Merus Nv Methods and means for the production of ig-like molecules
LT3597037T (lt) 2012-06-12 2021-06-10 Regeneron Pharmaceuticals, Inc. Humanizuoti gyvūnai, išskyrus žmones, su apribotu imunoglobulino sunkiosios grandinės lokusu
RU2664187C2 (ru) 2013-02-06 2018-08-15 Регенерон Фармасьютикалз, Инк. Разработка иммуногена на основе в-клеточной линии дифференцировки с использованием гуманизированных животных
US20140245468A1 (en) * 2013-02-20 2014-08-28 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
EP2967012B1 (en) * 2013-03-14 2020-09-16 Erasmus University Medical Center Rotterdam Transgenic non-human mammal for antibody production
WO2014141192A1 (en) * 2013-03-15 2014-09-18 Erasmus University Medical Center Generation of heavy chain-only antibodies
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
DE112014004537T5 (de) 2013-10-01 2016-07-21 Kymab Limited Tiermodelle und therapeutische Moleküle
JP6267986B2 (ja) * 2014-02-13 2018-01-24 株式会社特殊免疫研究所 ヒトの特定分子と結合する分子標的物質のｉｎｖｉｖｏ評価法
KR102276752B1 (ko) * 2014-03-21 2021-07-13 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
ES2762640T3 (es) 2014-03-21 2020-05-25 Regeneron Pharma Proteínas VL de unión a antígeno que exhiben diferentes características de unión
SG11201701040XA (en) 2014-09-19 2017-03-30 Regeneron Pharma Chimeric antigen receptors
WO2016149678A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
KR20230006929A (ko) 2016-01-13 2023-01-11 리제너론 파마슈티칼스 인코포레이티드 조작된 중쇄 다양성 영역을 갖는 설치류
WO2017143062A1 (en) 2016-02-16 2017-08-24 Regeneron Pharmaceuticals, Inc. Non-human animals having a mutant kynureninase gene
EP4368637A3 (en) 2016-05-20 2024-07-10 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
WO2017210586A1 (en) 2016-06-03 2017-12-07 Regeneron Pharmaceuticals, Inc. Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
WO2017214089A1 (en) 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
HUE052087T2 (hu) * 2016-11-04 2021-04-28 Regeneron Pharma Génmódosított immunglobulin lambda könnyûlánc lókusszal rendelkezõ nem humán élõlények
US11122042B1 (en) 2017-05-12 2021-09-14 F5 Networks, Inc. Methods for dynamically managing user access control and devices thereof
WO2018226861A1 (en) 2017-06-07 2018-12-13 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
TWI827567B (zh) 2017-12-05 2024-01-01 美商再生元醫藥公司 具有經改造免疫球蛋白λ輕鏈的非人類動物及其用途
JP2021519062A (ja) 2018-03-24 2021-08-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ペプチド−ｍｈｃ複合体に対する治療用抗体を生成するための遺伝子改変非ヒト動物、ならびにその作製方法および使用方法
CA3093850A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
MA52626A (fr) 2018-05-17 2021-03-24 Regeneron Pharma Anticorps anti-cd63, conjugués et leurs utilisations
WO2019240999A1 (en) * 2018-06-13 2019-12-19 Crystal Bioscience Inc. Camelization of a human variable domain by gene conversion
CA3103646C (en) 2018-06-14 2023-06-27 Regeneron Pharmaceuticals, Inc. Non-human animals capable of engineered dh-dh rearrangement and uses thereof
EP3927832A4 (en) 2019-02-18 2022-11-30 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH A HUMANIZED IMMUNOGLOBULIN LOCUS
MX2021009855A (es) 2019-02-22 2021-09-10 Regeneron Pharma Roedores que tienen canales de sodio modificados geneticamente y metodos de uso de los mismos.
EP3979790A1 (en) 2019-06-05 2022-04-13 Regeneron Pharmaceuticals, Inc. Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
EP3785536B1 (en) 2019-08-28 2022-01-26 Trianni, Inc. Adam6 knockin mice
WO2021113297A1 (en) 2019-12-02 2021-06-10 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
JP2023529846A (ja) 2020-06-02 2023-07-12 バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド 共通軽鎖免疫グロブリン遺伝子座を有する遺伝子改変非ヒト動物
JP2023540808A (ja) 2020-09-11 2023-09-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗原特異的抗体の同定及び産生
CN116848254A (zh) 2020-12-16 2023-10-03 瑞泽恩制药公司 表达人源化Fcα受体的小鼠
US20220195038A1 (en) 2020-12-23 2022-06-23 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
AU2021410655A1 (en) 2020-12-23 2023-06-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
JP7579462B2 (ja) 2021-04-20 2024-11-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アルテミンに対するヒト抗体及びその使用方法
WO2024015816A1 (en) 2022-07-12 2024-01-18 Regeneron Pharmaceuticals, Inc. Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof
WO2024173248A1 (en) 2023-02-13 2024-08-22 Regeneron Pharmaceuticals, Inc. Treatment of muscle related disorders with anti-human cacng1 antibodies

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
RU2151612C1 (ru) * 1992-12-01 2000-06-27 Протеин Дизайн Лэбс, Инк. Гуманизированный иммуноглобулин, специфичный для белка l-селектина человека
ATE387495T1 (de) * 1996-12-03 2008-03-15 Amgen Fremont Inc Vollkommen humane antikörper die egfr binden
CN1203922A (zh) * 1997-03-21 1999-01-06 三共株式会社 人源化抗人fas抗体
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
RU10506U1 (ru) 1999-04-08 1999-08-16 Кривулин Виталий Николаевич Ручной культиватор
EP1183344A4 (en) * 1999-05-27 2003-06-25 Human Genome Sciences Inc ADAM POLYNUCLEOTIDES AND POLYPEPTIDES
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7034134B2 (en) 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
KR100770065B1 (ko) * 2001-05-11 2007-10-24 기린 파마 가부시끼가이샤 인간 항체 λ 경쇄 유전자를 포함하는 인간 인공 염색체및 자손 전달 가능한 상기 인간 인공 염색체를 포함하는비인간 동물
US7473557B2 (en) 2001-06-06 2009-01-06 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
WO2003031656A1 (en) 2001-10-05 2003-04-17 United States Environmental Protection Agency Genetic testing for male factor infertility
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
JP4099646B2 (ja) 2002-06-04 2008-06-11 株式会社安川電機 ボイスコイルモータ
EP1523496B1 (en) 2002-07-18 2011-06-29 Merus B.V. Recombinant production of mixtures of antibodies
RU2251699C1 (ru) 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
PL2767161T3 (pl) 2004-10-19 2018-09-28 Regeneron Pharmaceuticals, Inc. Sposób wytwarzania zwierzęcia homozygotycznego pod względem modyfikacji genetycznej
ES2318384T3 (es) 2005-06-30 2009-05-01 Borealis Technology Oy Capa exterior de funda para cables de potencia o de comuniccion.
EP2505058A1 (en) * 2006-03-31 2012-10-03 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
EP2374818B1 (en) 2006-06-02 2012-12-19 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human IL-6 receptor
US9693539B2 (en) 2007-08-10 2017-07-04 E. R. Squibb & Sons, L.L.C. HCO32 and HCO27 and related examples
US7659842B2 (en) 2007-10-24 2010-02-09 Infineon Technologies Ag Quantization error reduction in PWM full-MASH converters
EP3889265A1 (en) 2008-09-30 2021-10-06 Ablexis, LLC Transgenic mice for the production of chimeric antibodies
SG172176A1 (en) * 2008-12-18 2011-07-28 Univ Erasmus Medical Ct Non-human transgenic animals expressing humanised antibodies and use therof
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
JP5399140B2 (ja) * 2009-06-18 2014-01-29 株式会社タイトー モールス信号通信システム
EP3241435B1 (en) * 2009-07-08 2021-05-26 Kymab Limited Animal models and therapeutic molecules
TR201906488T4 (tr) 2009-12-10 2019-05-21 Regeneron Pharma Ağır zincir antikor üreten fareler.
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
RS59001B1 (sr) 2010-02-08 2019-08-30 Regeneron Pharma Miš sa zajedničkim lakim lancem
SG186238A1 (en) 2010-06-17 2013-01-30 Kymab Ltd Animal models and therapeutic molecules
PT2550363E (pt) 2011-02-25 2015-03-16 Regeneron Pharma Ratinhos adam6
PT3865581T (pt) 2011-08-05 2024-10-04 Regeneron Pharmaceuticals Inc Murganhos da cadeia leve universal humanizada
BR112014008775A8 (pt) 2011-10-17 2017-09-12 Regeneron Pharma Métodos para produzir camundongos com locus restrito de cadeia pesada de imunoglobulina, para obter célula ou tecido de camundongos, para produzir sequência de ácido nucleico que codifica domínio variável de cadeia pesada humano, bem como ácido nucleico
GB201118579D0 (en) 2011-10-27 2011-12-07 Micromass Ltd Control of ion populations
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
SG10201605675WA (en) 2011-12-20 2016-09-29 Regeneron Pharma Humanized light chain mice

Also Published As

Publication number Publication date
KR101387377B1 (ko) 2014-04-21
US9932408B2 (en) 2018-04-03
PT2738258T (pt) 2019-12-10
US20150201589A1 (en) 2015-07-23
AU2020201279A1 (en) 2020-03-12
CY1122459T1 (el) 2021-01-27
DK2578688T1 (da) 2014-11-24
HRP20150262T1 (hr) 2015-04-10
AU2012243291A1 (en) 2013-05-09
CY1122820T1 (el) 2021-05-05
US20120322108A1 (en) 2012-12-20
RS53880B1 (en) 2015-08-31
EP2738258B2 (en) 2023-02-01
EP2738258B1 (en) 2019-09-25
CN105861548B (zh) 2020-01-10
EP2550363B1 (en) 2014-12-10
RS59661B2 (sr) 2023-06-30
DK2550363T3 (en) 2015-03-23
LT2738259T (lt) 2020-03-10
SI4067496T1 (sl) 2023-07-31
AU2015238806A1 (en) 2015-10-29
DK2578688T4 (da) 2023-05-08
RU2722373C2 (ru) 2020-05-29
US10905108B2 (en) 2021-02-02
PL4067496T3 (pl) 2023-07-31
SI2578688T1 (sl) 2019-11-29
RU2016109443A3 (xx) 2019-07-24
EP4067496A1 (en) 2022-10-05
LT2738258T (lt) 2020-01-10
DK2738259T3 (da) 2020-02-17
BR112013021771A2 (pt) 2017-07-04
HRP20230526T1 (hr) 2023-09-01
RU2016109443A (ru) 2018-11-26
EP2578688B1 (en) 2019-07-24
US20180362663A1 (en) 2018-12-20
ES2758974T5 (es) 2023-06-08
EP2738258A2 (en) 2014-06-04
US10072095B2 (en) 2018-09-11
DK2738258T1 (da) 2014-11-24
NZ718688A (en) 2017-07-28
MX343009B (es) 2016-10-21
SI2738259T1 (sl) 2020-06-30
PL2550363T3 (pl) 2015-05-29
IL261243A (en) 2018-10-31
FI4067496T3 (fi) 2023-05-24
IL226727A (en) 2016-08-31
US10694725B2 (en) 2020-06-30
EP2738259A2 (en) 2014-06-04
NZ776770A (en) 2023-03-31
US8642835B2 (en) 2014-02-04
HRP20191895T1 (hr) 2020-01-10
ES2748832T3 (es) 2020-03-18
US20130254911A1 (en) 2013-09-26
EP2813573A1 (en) 2014-12-17
JP2016135143A (ja) 2016-07-28
PL2738258T5 (pl) 2023-05-15
SI2550363T1 (sl) 2015-04-30
US20150210776A1 (en) 2015-07-30
IL273986A (en) 2020-05-31
CA2820824A1 (en) 2012-10-18
DK2813573T1 (da) 2015-01-12
DK4067496T3 (da) 2023-06-26
IL268671B (en) 2020-05-31
JP5866127B2 (ja) 2016-02-17
MX2020009714A (es) 2020-10-07
EP2738258A3 (en) 2014-09-24
EP3744850A1 (en) 2020-12-02
MX2013009649A (es) 2013-09-26
PT2550363E (pt) 2015-03-16
US20180346599A1 (en) 2018-12-06
ES2758974T3 (es) 2020-05-07
HUE046081T2 (hu) 2020-01-28
PL2738258T3 (pl) 2020-08-24
HUE024534T2 (hu) 2016-01-28
EP2550363A1 (en) 2013-01-30
LT4067496T (lt) 2023-06-12
EP4067496B1 (en) 2023-03-29
CY1122205T1 (el) 2020-11-25
US20210105984A1 (en) 2021-04-15
RU2013125717A (ru) 2014-12-10
DK2738259T1 (da) 2014-11-24
ES2805364T3 (es) 2021-02-11
HK1201292A1 (en) 2015-08-28
HRP20192311T4 (hr) 2023-05-12
EP2738259A3 (en) 2014-07-30
JP2022071051A (ja) 2022-05-13
NZ703609A (en) 2016-04-29
HRP20191895T4 (hr) 2023-05-12
US10577430B2 (en) 2020-03-03
HUE062552T2 (hu) 2023-11-28
FI2578688T4 (fi) 2023-05-05
CN105861548A (zh) 2016-08-17
FI2738258T4 (fi) 2023-05-05
NZ612643A (en) 2015-06-26
ES2770424T3 (es) 2020-07-01
NZ731926A (en) 2021-07-30
RS59661B1 (sr) 2020-01-31
DK2578688T3 (da) 2019-10-28
EP2738259B1 (en) 2019-11-27
DE12192727T1 (de) 2013-07-11
KR20130116375A (ko) 2013-10-23
SG192933A1 (en) 2013-09-30
US8697940B2 (en) 2014-04-15
RS59413B2 (sr) 2023-06-30
PL2578688T3 (pl) 2020-05-18
IL261243B (en) 2019-08-29
PT4067496T (pt) 2023-06-07
AU2012243291B2 (en) 2015-07-09
PL2738259T3 (pl) 2020-08-24
DE12716101T1 (de) 2013-05-08
DE14154918T1 (de) 2014-08-21
EP2578688A1 (en) 2013-04-10
ES2532487T3 (es) 2015-03-27
SI2738258T2 (sl) 2023-05-31
JP2019187446A (ja) 2019-10-31
LT2578688T (lt) 2019-11-11
US10905109B2 (en) 2021-02-02
CY1116301T1 (el) 2017-02-08
JP2015107131A (ja) 2015-06-11
IL273986B (en) 2021-04-29
SI2578688T2 (sl) 2023-05-31
CN103429746B (zh) 2016-05-11
HUE046746T2 (hu) 2020-03-30
ME02106B (me) 2015-10-20
CY1126091T1 (el) 2023-11-15
RS59413B1 (sr) 2019-11-29
HRP20200294T1 (hr) 2020-05-29
AU2022206806A1 (en) 2022-08-18
SG10201913160QA (en) 2020-03-30
PT2578688T (pt) 2019-10-24
US11950578B2 (en) 2024-04-09
WO2012141798A1 (en) 2012-10-18
EP2813573B1 (en) 2020-04-22
DK2738258T3 (da) 2019-12-16
MY172713A (en) 2019-12-11
PT2738259T (pt) 2020-02-18
ME03537B (xx) 2020-04-20
HRP20192311T1 (hr) 2020-03-20
AU2017251802A1 (en) 2017-11-16
PL2578688T5 (pl) 2023-05-29
DK2738258T4 (da) 2023-05-08
US20180345760A1 (en) 2018-12-06
ME03732B (me) 2021-01-20
RU2582261C2 (ru) 2016-04-20
RS59929B1 (sr) 2020-03-31
SG10201913155QA (en) 2020-02-27
US20180346598A1 (en) 2018-12-06
HK1174490A1 (en) 2013-06-14
DE14176593T1 (de) 2015-03-05
DK4067496T5 (da) 2024-07-22
JP2018143250A (ja) 2018-09-20
ES2748832T5 (es) 2023-06-08
RS64280B1 (sr) 2023-07-31
IN2013CN07629A (xx) 2015-08-07
ZA201305998B (en) 2016-07-27
SI2738258T1 (sl) 2020-01-31
JP2014110814A (ja) 2014-06-19
DE14154967T1 (de) 2014-08-28
CN103429746A (zh) 2013-12-04
IL268671A (en) 2019-10-31
HUE047687T2 (hu) 2020-05-28
EP2578688B2 (en) 2023-02-08
ES2946169T3 (es) 2023-07-13
BR112013021771B1 (pt) 2022-11-16
US20210105985A1 (en) 2021-04-15
US9944716B2 (en) 2018-04-17
SG10201405135RA (en) 2014-10-30
US20140213773A1 (en) 2014-07-31
US20240306617A1 (en) 2024-09-19
JP2014507137A (ja) 2014-03-27

Similar Documents

Publication Publication Date Title
SMT201500061B (it) Topi adam6
DK2679009T3 (da) Multi-metrik filtrering
DK2744810T4 (da) Tenofovir-alafenamid-hemifumarat
DK2769050T3 (da) Propsensor
BR112014000879A2 (pt) deflegmador
DK3272861T3 (da) Alpha-galactosidase-sammensætninger
DE102011100082A8 (de) Traygreifvorrichtung
DE112011104936A5 (de) Stanzstauchniet
DE112012000958A5 (de) Handsäge
DK2476953T3 (da) Fluidbedkedel
DE112012002458A5 (de) Hydrotransformator
DE112012000819A5 (de) Gurtbandfänger
DE112012005313A5 (de) Leuchtbild
DK2526750T3 (da) Høbjærgningsmaskine
DE112012001294T8 (de) Umspritzungsverfahren
DE102011117169A8 (de) Absetzplattenanordnung
DE112011105396A5 (de) Nachverfestigungsverfahren
FI9542U1 (fi) Kannakealusta
FI9298U1 (fi) Kannatin
FI9288U1 (fi) Ruukku
UA22483S (uk) Скатерка
UA22481S (uk) Скатерка
UA22482S (uk) Скатерка
UA22480S (uk) Скатерка
DK2681057T3 (da) Nanofiber-mærkning